The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca
Consulting or Advisory Role - Agendia; AstraZeneca; Lilly; MSD; Novartis; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
 
Virginia G. Kaklamani
Honoraria - AstraZeneca; daichi; Genentech; Genomic Health; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; Menarini; Puma Biotechnology; tersera; tersera
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Genentech; Genomic Health; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology
Research Funding - Eisai
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; GE Healthcare; GlaxoSmithKline; Lilly; Menarini; Novartis; Pfizer; Rain Oncology; Sanofi (Inst)
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Menarini Group; Novartis; Pfizer; Rain Oncology; Roche
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Prolynx (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Alberto J. Montero
Honoraria - AstraZeneca; Celgene; OncoSec
Consulting or Advisory Role - New Century Health; Paragon healthcare; Welwaze
(OPTIONAL) Uncompensated Relationships - Roche
 
Marie-Ange Mouret-Reynier
No Relationships to Disclose
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagan (Inst)
 
Donatienne Taylor
No Relationships to Disclose
 
Frederic Forget
Travel, Accommodations, Expenses - ipsen; Teva
 
Kathleen Kiernan Harnden
Honoraria - E-Health Now
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
 
Hung T. Khong
Stock and Other Ownership Interests - agenus; Lipocine; MEI Pharma; MustangBio; TG Therapeutics; Tiziana Life Sciences; Vaxart
Consulting or Advisory Role - Celcuity
Research Funding - AstraZeneca
 
Judit Kocsis
No Relationships to Disclose
 
Florence Dalenc
No Relationships to Disclose
 
Patrick Michael Dillon
Research Funding - Daichi Sankyo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Tolero Pharmaceuticals (Inst)
 
Simon Waters
Honoraria - Novartis Pharmaceuticals UK Ltd.
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Novartis Pharmaceuticals UK Ltd.; Sanofi/Aventis
 
José A. García-Sáenz
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Deloitte; G1 Therapeutics; Gilead Sciences; Macrogenics; Menarini; Novartis; Novartis; Radius Health; Roche; Servier
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Simona Scartoni
Employment - Menarini Group; Stemline Therapeutics
 
Nassir Habboubi
Employment - Stemline Therapeutics
Leadership - Stemline Therapeutics
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)